Does the media refer more to BNTX or REGN?

In the previous week, BioNTech and BioNTech both had 28 articles in the media. Regeneron Pharmaceuticals' average media sentiment score of 0.58 beat BioNTech's score of 0.32 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ARGX or BNTX?

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 14.70 $1.29B $26.04 38.34 BioNTech $2.65B 9.28 -$1.29B -$7.83 N/A

Is ARGX or BNTX more profitable?

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% BioNTech -63.54% -6.86% -6.00%

Does the media favor ARGX or BNTX?

In the previous week, BioNTech had 24 more articles in the media than argenex. MarketBeat recorded 28 mentions for BioNTech and 4 mentions for argenex. argenex's average media sentiment score of 0.45 beat BioNTech's score of 0.32 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, BNTX or MRNA?

BioNTech has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $2.65B 9.28 -$1.29B -$7.83 N/A Moderna $2.21B 28.04 -$2.82B -$7.99 N/A

Is BNTX or MRNA more profitable?

BioNTech has a net margin of -63.54% compared to Moderna's net margin of -141.43%. BioNTech's return on equity of -6.86% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Moderna -141.43% -28.30% -19.39%

Does the media favor BNTX or MRNA?

In the previous week, Moderna had 7 more articles in the media than BioNTech. MarketBeat recorded 35 mentions for Moderna and 28 mentions for BioNTech. Moderna's average media sentiment score of 0.40 beat BioNTech's score of 0.32 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Moderna 12 Very Positive mention(s) 10 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, BNTX or NTRA?

Natera has lower revenue, but higher earnings than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $2.65B 9.28 -$1.29B -$7.83 N/A Natera $2.31B 22.73 -$208.16M -$1.36 N/A

Is BNTX or NTRA more profitable?

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Natera -7.11% -11.38% -7.87%

Does the media prefer BNTX or NTRA?

In the previous week, BioNTech had 16 more articles in the media than Natera. MarketBeat recorded 28 mentions for BioNTech and 12 mentions for Natera. Natera's average media sentiment score of 1.08 beat BioNTech's score of 0.32 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Natera 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or RVMD?

In the previous week, BioNTech had 15 more articles in the media than Revolution Medicines. MarketBeat recorded 28 mentions for BioNTech and 13 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.89 beat BioNTech's score of 0.32 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

BioNTech (BNTX) Competitors

$96.97 -1.69 (-1.71%)

As of 10:18 AM Eastern

Compare

BNTX vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy BioNTech stock or one of its competitors? BioNTech's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioNTech compare to Regeneron Pharmaceuticals?

BioNTech (NASDAQ:BNTX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to BioNTech's net margin of -63.54%. Regeneron Pharmaceuticals' return on equity of 13.47% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Regeneron Pharmaceuticals has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.28	-$1.29B	-$7.83	N/A
Regeneron Pharmaceuticals	$15.53B	5.18	$4.50B	$40.46	19.30

15.5% of BioNTech shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.6%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. BioNTech pays out -19.5% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. BioNTech is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioNTech presently has a consensus price target of $126.00, suggesting a potential upside of 29.63%. Regeneron Pharmaceuticals has a consensus price target of $802.18, suggesting a potential upside of 2.70%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts clearly believe BioNTech is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, BioNTech and BioNTech both had 28 articles in the media. Regeneron Pharmaceuticals' average media sentiment score of 0.58 beat BioNTech's score of 0.32 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Regeneron Pharmaceuticals beats BioNTech on 10 of the 18 factors compared between the two stocks.

How does BioNTech compare to argenex?

argenex (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

60.3% of argenex shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

argenex has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

In the previous week, BioNTech had 24 more articles in the media than argenex. MarketBeat recorded 28 mentions for BioNTech and 4 mentions for argenex. argenex's average media sentiment score of 0.45 beat BioNTech's score of 0.32 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

argenex presently has a consensus target price of $1,158.61, suggesting a potential upside of 16.06%. BioNTech has a consensus target price of $126.00, suggesting a potential upside of 29.63%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
BioNTech	-63.54%	-6.86%	-6.00%

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	14.70	$1.29B	$26.04	38.34
BioNTech	$2.65B	9.28	-$1.29B	-$7.83	N/A

Summary

argenex beats BioNTech on 13 of the 17 factors compared between the two stocks.

How does BioNTech compare to Moderna?

BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

BioNTech has a net margin of -63.54% compared to Moderna's net margin of -141.43%. BioNTech's return on equity of -6.86% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Moderna	-141.43%	-28.30%	-19.39%

BioNTech has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.28	-$1.29B	-$7.83	N/A
Moderna	$2.21B	28.04	-$2.82B	-$7.99	N/A

BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

BioNTech currently has a consensus target price of $126.00, suggesting a potential upside of 29.63%. Moderna has a consensus target price of $76.72, suggesting a potential downside of 50.58%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Moderna had 7 more articles in the media than BioNTech. MarketBeat recorded 35 mentions for Moderna and 28 mentions for BioNTech. Moderna's average media sentiment score of 0.40 beat BioNTech's score of 0.32 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Moderna	12 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

BioNTech beats Moderna on 13 of the 17 factors compared between the two stocks.

How does BioNTech compare to Natera?

BioNTech (NASDAQ:BNTX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Natera has lower revenue, but higher earnings than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.28	-$1.29B	-$7.83	N/A
Natera	$2.31B	22.73	-$208.16M	-$1.36	N/A

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Natera	-7.11%	-11.38%	-7.87%

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioNTech presently has a consensus price target of $126.00, suggesting a potential upside of 29.63%. Natera has a consensus price target of $330.83, suggesting a potential downside of 9.02%. Given BioNTech's higher possible upside, equities research analysts clearly believe BioNTech is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, BioNTech had 16 more articles in the media than Natera. MarketBeat recorded 28 mentions for BioNTech and 12 mentions for Natera. Natera's average media sentiment score of 1.08 beat BioNTech's score of 0.32 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Natera	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Summary

Natera beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

BioNTech (NASDAQ:BNTX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Revolution Medicines has lower revenue, but higher earnings than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.28	-$1.29B	-$7.83	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A

In the previous week, BioNTech had 15 more articles in the media than Revolution Medicines. MarketBeat recorded 28 mentions for BioNTech and 13 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.89 beat BioNTech's score of 0.32 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

BioNTech presently has a consensus price target of $126.00, indicating a potential upside of 29.63%. Revolution Medicines has a consensus price target of $226.17, indicating a potential upside of 17.90%. Given BioNTech's higher probable upside, research analysts clearly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

BioNTech and Revolution Medicines tied by winning 8 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.65B	$3.88B	$7.20B	$14.00B
Dividend Yield	N/A	3.65%	2.57%	12.64%
P/E Ratio	-12.45	13.94	274.07	25.48
Price / Sales	9.28	1,523.69	676.41	100.02
Price / Cash	71.78	109.14	77.01	51.20
Price / Book	1.01	15.46	10.47	6.27
Net Income	-$1.29B	-$22.78M	$3.48B	$358.12M
7 Day Performance	0.49%	-1.22%	1.05%	1.24%
1 Month Performance	4.80%	-1.77%	-0.04%	-2.22%
1 Year Performance	0.93%	35.53%	18.13%	4.93%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	4.1358 of 5 stars	$97.20 -1.5%	$126.00 +29.6%	+0.5%	$24.65B	$2.65B	N/A	7,807	Analyst Forecast Insider Trade
REGN Regeneron Pharmaceuticals	3.7525 of 5 stars	$827.72 flat	$800.36 -3.3%	+34.8%	$85.22B	$14.34B	20.46	15,410
ARGX argenex	4.4714 of 5 stars	$1,033.15 flat	$1,158.61 +12.1%	+35.6%	$64.63B	$4.25B	39.68	1,863
MRNA Moderna	2.1115 of 5 stars	$145.55 flat	$76.72 -47.3%	+532.3%	$58.11B	$1.94B	N/A	4,700	Trending News Insider Trade Gap Up
NTRA Natera	1.9466 of 5 stars	$328.18 flat	$319.38 -2.7%	+108.8%	$47.31B	$2.31B	N/A	6,140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does BioNTech compare to Regeneron Pharmaceuticals?

Summary

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Moderna?

Summary

How does BioNTech compare to Natera?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does BioNTech compare to Regeneron Pharmaceuticals?

Is BNTX or REGN more profitable?

Which has stronger valuation & earnings, BNTX or REGN?

Do institutionals & insiders have more ownership in BNTX or REGN?

Which has more risk & volatility, BNTX or REGN?

Is BNTX or REGN a better dividend stock?

Do analysts prefer BNTX or REGN?

Does the media refer more to BNTX or REGN?

Summary

How does BioNTech compare to argenex?

Do insiders and institutionals hold more shares of ARGX or BNTX?

Which has more volatility & risk, ARGX or BNTX?

Does the media favor ARGX or BNTX?

Do analysts prefer ARGX or BNTX?

Is ARGX or BNTX more profitable?

Which has stronger earnings and valuation, ARGX or BNTX?

Summary

How does BioNTech compare to Moderna?

Is BNTX or MRNA more profitable?

Which has preferable earnings & valuation, BNTX or MRNA?

Which has more volatility & risk, BNTX or MRNA?

Do analysts prefer BNTX or MRNA?

Do insiders and institutionals hold more shares of BNTX or MRNA?

Does the media favor BNTX or MRNA?

Summary

How does BioNTech compare to Natera?

Which has preferable valuation & earnings, BNTX or NTRA?

Is BNTX or NTRA more profitable?

Do insiders & institutionals hold more shares of BNTX or NTRA?

Do analysts prefer BNTX or NTRA?

Does the media prefer BNTX or NTRA?

Which has more risk & volatility, BNTX or NTRA?

Summary

How does BioNTech compare to Revolution Medicines?

Which has preferable valuation and earnings, BNTX or RVMD?

Does the media prefer BNTX or RVMD?

Do institutionals & insiders believe in BNTX or RVMD?

Which has more risk & volatility, BNTX or RVMD?

Do analysts prefer BNTX or RVMD?

Is BNTX or RVMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools